Navigation Links
Altheus Therapeutics announces completed enrollment of ZA201, a Phase 2 clinical trial of Zoenasa for distal ulcerative colitis
Date:1/9/2014

OKLAHOMA CITY, Jan. 9, 2014 /PRNewswire/ --  Altheus Therapeutics, Inc., announced that it has completed enrollment for ZA201, a 6-week, double-blind, active-controlled Phase 2 clinical trial of the efficacy and safety of Zoenasa® Rectal Gel in approximately 120 adult patients with left-sided, or distal, ulcerative colitis.  Topline results are expected in to be available in March or early April. 

(Logo:  http://photos.prnewswire.com/prnh/20140109/DA43446LOGO)

"Positive ZA201 results will validate the entire Zoenasa platform, so we are pleased to have achieved this milestone," commented Dennis Schafer, President and CEO of Altheus. "We look forward to gaining alignment on our registration program with the FDA and other Health Authorities as the next step to making Zoenasa available to IBD patients."

Nearly 1.2 million Americans suffer from inflammatory bowel disease. The two most common forms, ulcerative colitis and Crohn's disease, are chronic lifelong conditions which significantly impact quality of life. Front-line treatment for ulcerative colitis is monotherapy with oral or rectal mesalamine.  However, many patients do not achieve symptomatic or endoscopic remission and must escalate to more expensive and risky treatments.   

Zoenasa is a patented, novel combination of two FDA-approved drugs, with well-established efficacy and safety records, that have been shown to act synergistically to improve the signs and symptoms of ulcerative colitis.  In animal models of colitis, Zoenasa resolved inflammation more rapidly and completely than mesalamine (the current front line standard of care). 

Zoenasa Rectal Gel is being investigated for the treatment of left-sided ulcerative colitis, which affects approximately 80% of ulcerative colitis patients.  The U.S. Food and Drug Administration also granted Zoenasa orphan designation for the treatment of pediatric ulcerative colitis.  An oral formulation of Zoenasa is in pre-clinical development.

About ZA201
The ZA201 clinical trial is a 6-week, double-blind, active-controlled Phase 2 study of the efficacy and safety of Zoenasa® Rectal Gel versus mesalamine standard enema therapy in approximately 120 adult patients with left-sided, or distal, ulcerative colitis. http://clinicaltrials.gov/ct2/show/NCT01586533.

About Altheus Therapeutics
Founded in 2007, Altheus Therapeutics, Inc., of Oklahoma City, OK, is a pharmaceutical development company focused on innovative therapies for the treatment of inflammatory bowel disease. http://altheustherapeutics.com.

Contact: Dennis Schafer, CEO
dschafer@altheustherapeutics.com
(405) 319-8180


'/>"/>
SOURCE Altheus Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Flexion Therapeutics Files Registration Statement for Proposed Initial Public Offering
4. G1 Therapeutics to Present at Biotech Showcase 2014
5. Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify and Progress High Potential Therapeutics
6. Mast Therapeutics Provides Enrollment Update On Phase 3 "EPIC" Study Of MST-188
7. Revamped Therapies Preventing Visual Impairment Primed to Revolutionize US Retinal Therapeutics Market
8. Agile Therapeutics Appoints Dr. Elizabeth Ijeoma Onyemelukwe Garner as Chief Medical Officer
9. Dr. Seth Rudnick Joins G1 Therapeutics as Executive Chairman
10. Advinus Therapeutics, a TATA Enterprise, Meets Year 1 Milestone in Drug Discovery Alliance
11. Specialised Therapeutics Australia Partners with Genomic Health Inc. to Deliver Novel Genomic Test to Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... Texas , Oct. 6, 2017   Provista, ... with more than $100 billion in purchasing power, today ... news and information. The Newsroom is the ... and industry trends, infographics, expert bios, news releases, slideshows ... having access to a wealth of resources at their ...
(Date:10/2/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... , and named its founder as Diplomat,s chief information ... Tennessee , will operate under Diplomat subsidiary Envoy ... for health care partners to include IT outsourcing, consulting, ... "In an interoperable world, technology delivers comprehensive insight and ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health ... technology. Applying the Purzorbâ„¢process to full spectrum CBD oil will revolutionize the rapidly growing ... form that can be easily incorporated into liquid products, while reducing costs to end ...
(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
Breaking Medicine News(10 mins):